首页> 外文期刊>Cornea >Intraductal meibomian gland probing relieves symptoms of obstructive meibomian gland dysfunction.
【24h】

Intraductal meibomian gland probing relieves symptoms of obstructive meibomian gland dysfunction.

机译:导管内睑板腺探查可缓解阻塞性睑板腺功能障碍的症状。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: To perform a retrospective evaluation of a new treatment for obstructive meibomian gland dysfunction (O-MGD) using invasive orifice penetration and intraductal probing. SETTING: Office-based ophthalmology private practice. METHODS: Medical charts of 25 consecutive patients with O-MGD (based on presence of lid margin or tarsal hyperemia, lid margin telangiectasia, thickening or irregularity, and meiboman gland orifice metaplasia) plus lid tenderness or symptoms of lid margin congestion were reviewed to evaluate the effect of probing on tenderness and congestion. RESULTS: Twenty-four of 25 patients (96%) had immediate postprobing relief, whereas all 25 patients (100%) had relief of symptoms by 4 weeks after procedure. Twenty patients (80%) only required 1 reatment and had an average of 11.5-month follow-up. Five patients (20%) had retreatment at an average of 4.6 months. All patients had symptom relief at time of last follow-up. Of 56 symptomatic and treated lids, 42 (75%) were upper lids. Patients frequently reported improvement in newly recognized but previously subclinical symptoms. CONCLUSIONS: Invasive orifice penetration and intraductal probing seems to provide lasting rapid symptom relief for patients with O-MGD. Probing findings in this study frequently included (1) mild resistance upon orifice penetration, (2) proximal duct gritty tactile and aural sensation suggestive of keratinized cellular debris, and (3) focal variable resistance deeper within the duct, which may be relieved with the probe, suggestive of fibrovascular tissue. Taken together, these findings may offer probing characteristics that may allow for a grading system for duct obstruction. The postprobing improvement of symptoms not previously appreciated supports the notion that meibomian gland disease exists subclinically.
机译:目的:使用侵入性小孔穿透和导管内探查对阻塞性睑板腺功能障碍(O-MGD)的新疗法进行回顾性评估。地点:基于办公室的眼科私人执业。方法:回顾了25例连续O-MGD患者的病历(根据眼睑边缘或睑缘充血,眼睑边缘毛细血管扩张,增厚或不规则以及梅博曼腺孔口化生)加上眼睑压痛或眼睑边缘充血症状,进行了评估探测对压痛和充血的影响。结果:25例患者中有24例(96%)术后立即缓解,而25例患者(100%)在术后4周后症状均得到缓解。 20名患者(80%)仅需要休息1次,平均随访11.5个月。五名患者(20%)平均接受了4.6个月的再治疗。所有患者在上次随访时症状均得到缓解。在56个有症状和经过处理的眼睑中,有42个(75%)是上眼睑。患者经常报告新认识到但以前属于亚临床症状的症状有所改善。结论:侵袭性小孔穿透和导管内探查似乎可以为O-MGD患者提供持久的快速症状缓解。该研究的探索性结果通常包括(1)孔口穿透后有轻度阻力,(2)提示角质化细胞碎片的近端管道坚硬触觉和听觉感觉,以及(3)导管内较深的局灶性可变阻力,可通过导管缓解探针,提示有纤维血管组织。综上所述,这些发现可能会提供探测特征,从而可能为导管阻塞提供分级系统。先前未发现的症状的探测后改善改善了睑板腺疾病在亚临床上存在的观点。

著录项

  • 来源
    《Cornea》 |2010年第10期|共8页
  • 作者

    Maskin SL;

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 眼科学;
  • 关键词

  • 入库时间 2022-08-18 09:43:31

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号